At a glance
- Originator ArQule
- Developer Merck & Co
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 03 Jan 2001 Discontinued-Preclinical for HIV infections treatment (Unknown route)
- 31 Jul 1998 No-Development-Reported for HIV infections treatment (Unknown route)